Team:Bay Area RSI

From 2009.igem.org

(Difference between revisions)

Latest revision as of 23:54, 21 October 2009



	Breast cancer is the second most common type of cancer diagnosed in women. RNAi has proven to be an effective mechanism in the silencing of oncogenes. Therefore, we have attempted to build a viable system for the delivery of RNAi into breast cancer cells. First, we inserted a shRNA sequence coding for the Raf-1 protein into an AAV cassette containing two ITR's, allowing it to reproduce itself in mammalian cells. This cassette was inserted into our chosen vector, the filamentous bacteriophage FUSE-55. An antibody sequence was then added to the phage plasmid near the coat protein sequence in order to target HER2. As an additional feature, we have fused Silicatein and Silintaphin to mStrepavidin, which will bind to a protein tag in the coat, forming silicate structures on the coat of the phage, thereby reducing the immunotoxicity of the bacteriophage in vivo.

Home	The Team	The Project	Parts Submitted to the Registry	Modeling	Notebook

(Or you can choose different headings. But you must have a team page, a project page, and a notebook page.)

@@ Line 1: / Line 1: @@
 {|align="justify"
-|You can write a background of your team here.  Give us a background of your team, the members, etc.  Or tell us more about something of your choosing.
+|
-|[[Image:RSI logo|200px|right|frame]]
+|[[Image:sunnyvale.jpeg|100px|right|frame]]
 |-
 |
-''Tell us more about your project.  Give us background.  Use this is the abstract of your project.  Be descriptive but concise (1-2 paragraphs)''
+|[[Image:IMG_1569.JPG|800px|thumb]]
-|[[Image:IMG_1569.JPG|400px|thumb]]
 |-
 |
-|align="center"|[[Team:Bay_Area_RSI | Our Team]]
+|align="center"|<br><br>''<font size="4">Breast cancer is the second most common type of cancer diagnosed in women. RNAi has proven to be an effective mechanism in the silencing of oncogenes. Therefore, we have attempted to build a viable system for the delivery of RNAi into breast cancer cells. First, we inserted a shRNA sequence coding for the Raf-1 protein into an AAV cassette containing two ITR's, allowing it to reproduce itself in mammalian cells. This cassette was inserted into our chosen vector, the filamentous bacteriophage FUSE-55. An antibody sequence was then added to the phage plasmid near the coat protein sequence in order to target HER2. As an additional feature, we have fused Silicatein and Silintaphin to mStrepavidin, which will bind to a protein tag in the coat, forming silicate structures on the coat of the phage, thereby reducing the immunotoxicity of the bacteriophage in vivo. </font>''<br><br><br><br><br>
 |}